Amager Hospital
- Address
- lock Available on a paid plan
Amager Hospital - Cardiovascular and Infectious Disease Research Center
Amager Hospital is a distinguished clinical research center with specialized expertise in cardiovascular disease prevention and treatment. The center leads multiple landmark trials investigating novel therapeutic approaches for heart failure, myocardial infarction, and atherosclerotic cardiovascular disease, demonstrating a comprehensive commitment to advancing cardiac care across the continuum from primary prevention to acute intervention.
- Heart failure prevention and management, including studies of aldosterone synthase inhibitors, hydralazine-ISDN combinations, and metabolic interventions
- Post-myocardial infarction care and secondary prevention strategies, particularly evaluating beta-blocker therapy in patients without reduced ejection fraction
- Primary prevention of atherosclerotic cardiovascular disease using innovative lipid-lowering therapies such as inclisiran
- Community-acquired pneumonia treatment optimization through local antibiotic delivery systems
Beyond cardiovascular research, Amager Hospital contributes to infectious disease and vaccine development studies. The center's research portfolio includes groundbreaking work on inhaled antibiotic delivery for pneumonia, offering alternatives to systemic antibiotic therapy, as well as pediatric immunization research focused on meningococcal disease prevention. This diverse expertise positions Amager Hospital as a leading institution in translating innovative therapeutic concepts into clinical practice across multiple medical disciplines.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 62 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 56 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1AstraZeneca AB2active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.3trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 111 other sites in Denmark
Therapeutic Area Benchmark — Denmark
Select a therapeutic area to compare against other sites in Denmark.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Denmark
Market Share
Country: Denmark
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Amager Hospital
lock Showing 1 of 19 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) | Amgen Inc. | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 62 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Apixaban | 2 | Unknown | 2022-11-24 | 2023-08-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.